A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency

EMBO Molecular Medicine

Volumn 7, Issue 4, 2015, Pages 438-449

  Liu, Chuan ^a,b,i   Ding, Hongyu ^a   Li, Xiaoxi ^a   Pallasch, Christian P ^c   Hong, Liya ^d   Guo, Dianwu ^d   Chen, Yi ^e   Wang, Difei ^f   Wang, Wei ^g   Wang, Yajie ^b,i   Hemann, Michael T ^h   Jiang, Hai ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d Hangzhou Huadong Medicine Group Biotechnology Institute Co Ltd   (China)

^e Crystal Biopharmaceutical LLC   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

ⁱ TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

HDAC; DNA repair; Dual targeting anticancer drug; Nitrogen mustard

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CHLORMETHINE; CY 190602; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DNA; DOXORUBICIN; FLUDARABINE; FUNCTIONAL GROUP; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE H2AX; HYDROXYL GROUP; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL VIABILITY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA REPAIR; DNA, NEOPLASM; DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE;

EID: 84926163466     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404580     Document Type: Article

References (53)

1. Aguado-Llera D, Hamidi T, Doménech R, Pantoja-Uceda D, Gironella M, Santoro J, Velázquez-Campoy A, Neira JL, Iovanna JL (2013) Deciphering the binding between Nupr1 and MSL1 and their DNA-repairing activity. PLoS ONE 8: e78101
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601
3. Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT (2011) Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117: 3585-3595
4. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375-379
5. Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27: 1492-1501
6. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman A-R, Kennedy R, Foster R, Mahoney J, Seiden MV et al (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5: 952-961
7. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840
8. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan Y-L, Simpson D, Craig M et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123: 2944-2952
9. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP (2009) Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462: 935-939
10. Garnock-Jones KP (2010) Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 70: 1703-1718
11. Gironella M, Malicet C, Cano C, Sandi MJ, Hamidi T, Tauil RMN, Baston M, Valaco P, Moreno S, Lopez F et al (2009) p8/nupr1 regulates DNA-repair activity after double-strand gamma irradiation-induced DNA damage. J Cell Physiol 221: 594-602
12. Gruber F, Mustjoki S, Porkka K (2009) Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 145: 581-597
13. Hasan S, Hassa PO, Imhof R, Hottiger MO (2001) Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis. Nature 410: 387-391
14. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204
15. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GCM (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159
16. Huang J, Wan B, Wu L, Yang Y, Dou Y, Lei M (2012) Structural insight into the regulation of MOF in the male-specific lethal complex and the non-specific lethal complex. Cell Res 22: 1078-1081
17. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078
18. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST et al (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213
19. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-1909
20. Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT (2011) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 7: 92-100
21. Kaidi A, Jackson SP (2013) KAT5 tyrosine phosphorylation couples chromatin sensing to ATM signalling. Nature 498: 70-74
22. Keating MJ, Bach C, Yasothan U, Kirkpatrick P (2008) Bendamustine. Nat Rev Drug Discov 7: 473-474
23. Kennedy RD, D'Andrea AD (2006) DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24: 3799-3808
24. Knauf W (2009) Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 9: 165-174
25. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27: 4378-4384
26. Knipscheer P, Räschle M, Smogorzewska A, Enoiu M, Ho TV, Schärer OD, Elledge SJ, Walter JC (2009) The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326: 1698-1701
27. Kolas NK, Chapman JR, Nakada S, Ylanko J, Chahwan R, Sweeney FD, Panier S, Mendez M, Wildenhain J, Thomson TM et al (2007) Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 318: 1637-1640
28. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN et al (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935
29. Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH-Y, Hsieh JJ-D (2010) Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467: 343-346
30. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, Jackson SP (2010) Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17: 1144-1151
31. Moldovan G-L, D'Andrea AD (2009) How the fanconi anemia pathway guards the genome. Annu Rev Genet 43: 223-249
32. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, Butler L, Galanty Y, Pangon L, Kiuchi T et al (2009) The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 462: 886-890
33. Nakada S, Tai I, Panier S, Al-Hakim A, Iemura S-I, Juang Y-C, O'Donnell L, Kumakubo A, Munro M, Sicheri F et al (2010) Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 466: 941-946
34. Niida H, Katsuno Y, Sengoku M, Shimada M, Yukawa M, Ikura M, Ikura T, Kohno K, Shima H, Suzuki H et al (2010) Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase. Genes Dev 24: 333-338
35. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11: 459-464
36. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, Botrugno OA, Parazzoli D, Oldani A, Minucci S et al (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471: 74-79
37. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823
38. Smith ER, Cayrou C, Huang R, Lane WS, Côté J, Lucchesi JC (2005) A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 25: 9175-9188
39. Stauffer D, Chang B, Huang J, Dunn A, Thayer M (2007) p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint. J Biol Chem 282: 9678-9687
40. Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES, Nakada S, Ylanko J, Olivarius S, Mendez M et al (2009) The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 136: 420-434
41. Stock W (2010) Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 51: 188-198
42. Sun Y, Jiang X, Chen S, Fernandes N, Price BD (2005) A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci USA 102: 13182-13187
43. Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR, Price BD (2009) Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 11: 1376-1382
44. Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N (2005) Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 48: 1019-1032
45. Taniguchi T, D'Andrea AD (2006) Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107: 4223-4233
46. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN (2013) Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther 12: 2078-2087
47. Van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJA, Isacoff WH, Hruban RH et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11: 7508-7515
48. Williams RT, Roussel MF, Sherr CJ (2006) Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103: 6688-6693
49. Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F, Lowe C, Carter A, Harris R, Pettitt AR et al (2008) DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 14: 3984-3992
50. Yanada M, Ohno R, Naoe T (2009) Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 89: 3-13
51. Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R et al (2013) Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. Am J Hematol 88: 955-960
52. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M (2007) Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168: 115-124
53. Zhang F, Zhang T, Teng Z-H, Zhang R, Wang J-B, Mei Q-B (2009) Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 8: 823-831